Symptomatic deep vein thrombosis ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with direct oral anticoagulants (DOAC) (very low certainty).
1 finding from 1 review
RR 5 [0.31, 79.94]
1 study · 8 participants
Very low
Spontaneous onset of labour ‐ not reported · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of labour ‐ not reported · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Caesarean section · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
Amniotic membranes sweeping showed no clear difference in caesarean section compared with vaginal/oral misoprostol (low certainty).
1 finding from 1 review
Spontaneous vaginal birth ‐ not reported · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Uterine hyperstimulation with/without fetal heart rate (FHR) changes ‐ not reported · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious maternal morbidity or death · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Neonatal death or serious neonatal perinatal morbidity · pregnant women carrying a live fetus at or near term (≥ 36 weeks' gestation).
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · SSNS in children
Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Continuing frequently relapsing or steroid‐dependent SSNS at 6 months · SSNS in children
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Relapse · SSNS in children
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Mean relapse rate/patient/month · SSNS in children
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: leucopenia · SSNS in children
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: hair loss · SSNS in children
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: all infections · SSNS in children
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse event nausea and vomiting (0 to 24 hours) · SSNS in children
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Birthweight (g) · opiate‐dependent pregnant women
1 finding from 1 review
APGAR score (APGAR score ) · opiate‐dependent pregnant women
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found